Finance

UK watchdog says it may accept remedies in $35 billion Synopsys-Ansys deal

Published by Global Banking & Finance Review

Posted on January 8, 2025

1 min read

· Last updated: January 27, 2026

Add as preferred source on Google
Illustration of Synopsys-Ansys merger considerations by UK watchdog - Global Banking & Finance Review
The image illustrates the UK competition regulator's review of the Synopsys-Ansys $35 billion merger, highlighting the potential remedies to address regulatory concerns over the deal.
Global Banking & Finance Awards 2026 — Call for Entries

UK Watchdog Considers Remedies for Synopsys-Ansys Deal

(Reuters) -The UK's competition regulator said on Wednesday it might accept remedies offered by chip design software maker Synopsys and Ansys to address the concerns raised over their $35 billion deal.

Synopsys announced its cash-and-stock deal for Ansys, whose software is used to make products ranging from airplanes to tennis rackets, in January last year.

The Competition and Markets Authority said the undertakings offered on Dec. 31 included the divestment of Ansys' power consumption analysis product for digital chips and Synopsys' sale of its global optics and photonics software business.

The CMA said it has until March 5 to decide whether to accept the undertakings, with the possibility to extend the deadline to May 6.

A Synopsys spokesperson said the companies are pleased with the regulator's decision, adding that the duo will maintain its "constructive and collaborative engagement" with the CMA.

(Reporting by Aby Jose Koilparambil and Prerna Bedi in Bengaluru; Editing by Shilpi Majumdar)

Key Takeaways

  • UK's CMA may accept remedies for Synopsys-Ansys deal.
  • Deal valued at $35 billion, announced last January.
  • Remedies include divesting Ansys' digital chip product.
  • Synopsys to sell its optics and photonics software.
  • Decision deadline set for March 5, extendable to May 6.

Frequently Asked Questions

What is the main topic?
The main topic is the UK's CMA considering remedies for the $35 billion Synopsys-Ansys deal to address competition concerns.
What remedies are proposed?
Proposed remedies include the divestment of Ansys' power consumption analysis product and Synopsys' optics and photonics software.
What is the deadline for the decision?
The CMA has until March 5 to decide on the remedies, with a possible extension to May 6.

Related Articles

More from Finance

Explore more articles in the Finance category